Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly's Phase 2 eloralintide-plus-tirzepatide regimen delivered 23.3% average weight loss at 48 weeks in obesity and Type 2 diabetes patients, versus 14.8% for high-dose tirzepatide alone. The efficacy signal supports amylin as a potentially significant new obesity-drug pathway, with Leerink estimating Lilly's eloralintide franchise could generate $23.2B in annual sales by 2035. Key risk is tolerability: 10.8% to 27.0% of combination-treatment patients discontinued because of side effects, versus 2.9% on tirzepatide alone, leaving Phase 3 confirmation critical.

Analysis

The investable read-through is less about a near-term revenue upgrade for LLY than a widening obesity-treatment TAM: a second mechanism creates a salvage pathway for inadequate GLP-1 responders and supports longer treatment duration rather than simple molecule-for-molecule substitution. Payers may ultimately reimburse sequencing or add-on use only if incremental weight loss translates into fewer diabetes, cardiovascular, or liver-disease events; absent outcomes evidence, combination pricing will face substantially greater utilization management than monotherapy.

The key economic vulnerability is persistence. High discontinuation converts headline efficacy into lower real-world drug revenue, worsens payer willingness to cover premium combinations, and could force dose titration that narrows the apparent advantage. Over the next 1-3 months, NVO is the cleaner clinical-commercial catalyst vehicle because its amylin program can establish the category's tolerability and launch economics; LLY's valuation impact should remain muted until Phase 3 design, discontinuation, and durability data clarify whether its program is a premium franchise or a niche rescue therapy.

A non-obvious beneficiary is ZEAL: validation that amylin can address GLP-1 nonresponders improves strategic value for petrelintide, where a large pharma acquirer could seek an independent mechanism rather than build internally. Conversely, pure incretin developers such as VKTX and ALT risk multiple compression over 6-18 months if the market concludes that durable obesity leadership requires multi-pathway regimens, although this is not yet a direct efficacy verdict on their assets.

Consensus is likely over-crediting peak-sales models that multiply trial efficacy by the broad obesity population. The addressable population may be large, but the commercial bottleneck is likely payer approval plus tolerability-adjusted persistence; Phase 3 discontinuation rates, not additional percentage points of weight loss, are the most important falsification variable. If combination discontinuation remains above roughly 15% or dose reductions materially erode incremental efficacy, the premium-combination thesis should be discounted.

Key Decisions for Investors

• Maintain LLY as a core long but do not add solely on Phase 2 enthusiasm; use Phase 3 protocol disclosure and subsequent discontinuation data as entry catalysts over the next 6-12 months. Add only if tolerability mitigation is credible; reduce incremental exposure if discontinuation remains above 15% or efficacy converges after treatment-policy analysis.
• Prefer a 3-6 month relative-value long NVO / short LLY trade in modest size ahead of the nearer commercial proof point for NVO's amylin franchise. Thesis: NVO has the earlier opportunity to set reimbursement and persistence benchmarks; stop out if NVO launch uptake or refill data indicate payer resistance or materially worse-than-expected persistence.
• Establish a small, event-driven long ZEAL basket position rather than chase broad obesity beta, with a 12-18 month horizon. The risk/reward is tied to clinical execution and partnering/M&A optionality; cap position size because independent amylin data and financing needs remain the critical missing inputs.
• Avoid shorting VKTX or ALT on this development alone. Set an alert for Phase 3 amylin persistence data and payer formulary language: evidence that combinations become standard-of-care would justify reassessing their terminal-value multiples and potentially pairing long ZEAL versus short single-mechanism obesity developers.